Top 10 Fetal Bovine Serum Companies

Why Are Fetal Bovine Serum Market Expanding?

Global Fetal Bovine Serum (FBS) Market is anticipated to increase from USD 1.072 billion in 2025 to USD 1.946 billion by 2035 at a CAGR of 6.14% during the forecast period 2025-2035. As per Market Research Future (MRFR), there are two major demand drivers powering the growth of the FBS market. These include the fast scaling up of cell-based therapy manufacturing and the speeding up of the global biopharmaceutical pipeline (WHO reported more than 20,000 active clinical trials across the globe in 2025).

The combination of the rise in life sciences R&D investments (which are expected to approach USD 200 billion globally in 2025), the increase in vaccine manufacturing capacity and the increase in regenerative medicine research, together underpin a structural demand that is not tied to the cycle.

Heat-inactivated FBS is the leading product category, accounting for 63% of sales in 2025. It is prized for its capacity to inactivate complement proteins and lower the risk of cytotoxicity in sensitive cell culture applications. Tagged FBS is the fastest-growing product type with rising use for enhanced cell tracking and fluorescence-based research methods in biotechnology and immunology. The highest proportion of applications is Research and Development with 58%, and the fastest growing application sector is Biotechnology.

The biggest end-use group is the Pharmaceutical Industry, accounting for 61%, driven by demand from biologic drug manufacturers, vaccine producers and cell therapy developers. The fastest-growing end-use category is Academic Research. Liquid FBS retains the largest share of 67% in the formulation; however, powdered FBS is gaining popularity owing to its longer shelf life and ease of cold chain logistics in the distribution of FBS in emerging markets.

Why These Companies Are Leading the Market?

MRFR outlines four structural pillars that define category leadership in the Fetal Bovine Serum Market: geographic sourcing diversification and supply chain resilience; quality certification depth (mycoplasma-free, virus-tested, biosafety-certified lots); platform breadth spanning FBS alongside complementary cell culture media and bioprocess consumables; and M&A strategy targeting supply chain vertical integration. In this industry, companies with regulated sourcing traceability and lot-to-lot consistency capabilities that pharmaceutical-grade customers require to support regulatory filings have the greatest revenue positions.

The main difference between the market leaders is the diversification of geographic sourcing. Thermo Fisher Scientific’s Gibco brand continues to source multi-origin FBS from the US, Australia and New Zealand, enabling supply redundancy and the option to match origin requirements to client regulatory demands in 160+ countries. An example of platform breadth is Corning Incorporated, which acquired Bovogen Biologicals in 2025 to add a premium Australian-origin supply of FBS to its current life sciences portfolio of cell culture containers, media and bioprocess consumables.

Merck KGaA (Sigma-Aldrich) leadership in quality certification sets the competitive position of the company with the most extensive portfolio of biosafety-tested and specialty-grade FBS lots, including gamma-irradiated, dialyzed and charcoal-stripped options, to support the most demanding pharmaceutical and clinical research customers. The acquisition strategy is a key driver of the consolidating position of Biowest and GE HealthCare (Cytiva). The companies are investing in production capacity of European origin in response to the increasing demand for EU-sourced FBS from biomanufacturers who are bound by EMA guidance on animal-derived products.

Top 10 Global Fetal Bovine Serum Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading fetal bovine serum companies globally, evaluated on the basis of revenue performance, market capitalization, geographic presence, product breadth, innovation strategy, and client base.

*Rankings based on MRFR analysis. Revenue figures sourced from official company filings and investor relations disclosures. CAGR reflects company-guided or analyst-estimated growth for FBS-relevant segments.

Detailed Company Profiles

1. Thermo Fisher Scientific (Gibco) | NYSE: TMO | Waltham, Massachusetts, USA

Thermo Fisher Scientific’s Gibco brand is the world’s leading supplier of fetal bovine serum (FBS). The company provides the broadest range of FBS grades – standard, heat-inactivated, dialyzed, charcoal-stripped, gamma-irradiated, and mycoplasma-tested lots – for pharmaceutical, academic, and clinical research customers. Gibco FBS is obtained from the United States, Australia and New Zealand to provide multi-origin supply redundancy, allowing customers to match serum origin to specific regulatory and geographic procurement requirements among 160+ countries. Thermo Fisher’s cell culture business combines FBS with proprietary cell culture media, supplements and bioprocess consumables to create a complete, single-source solution for mammalian cell culture laboratories working on drug research, vaccine manufacture and regenerative medicine.

2. Corning Incorporated | NYSE: GLW | Corning, New York, USA

Corning Incorporated participates in the fetal bovine serum market through its Life Sciences segment, supplying FBS and animal sera alongside its leading portfolio of cell culture vessels, flasks, multiwell plates, and bioprocess containers to research institutions, pharmaceutical companies, and biomanufacturers worldwide. Corning's FBS product range covers standard, heat-inactivated, and specialty-grade lots tested for sterility, mycoplasma, and adventitious agents, meeting the quality requirements of cGMP biomanufacturing and academic cell culture applications. The company serves over 75 countries through an extensive distribution network, backed by quality assurance systems compliant with ISO 9001 and cGMP laboratory standards.

3. Merck KGaA (Sigma-Aldrich) | XETRA: MRK | Darmstadt, Germany

Merck KGaA’s Life Science division provides fetal bovine serum and specialty animal sera under the Sigma-Aldrich, Millipore and Merck brands with one of the most extensive FBS product portfolios on the market including standard, heat-inactivated, gamma-irradiated, dialyzed, charcoal-dextran-stripped and hormone-free grades for highly specialized cell culture and endocrinology research applications. Sigma-Aldrich FBS is a preferred source of FBS for biopharmaceutical customers who are sensitive to regulatory filings in Europe and North America. The company’s FBS lots are rigorously tested for viruses, screened for mycoplasma and documented with a certificate of analysis in accordance with EMA and FDA guidance on animal-derived materials. Merck KGaA’s Life Science business reaches more than 66 countries through a global distribution system. It offers both conventional catalog FBS lots and tailored bulk serum procurement services for big biomanufacturing customers.

4. Biowest | Private | Nuaille, France

Company Overview. Biowest is a European specialist manufacturer and supplier of fetal bovine serum and other animal-derived biological products for cell culture. Biowest offers a diverse product portfolio including standard-grade, heat-inactivated, dialyzed, gamma-irradiated and specialty FBS lots sourced from EU, US, Australian and New Zealand bovine herds. The company’s FBS supply chain is based on the creation of serum of European origin, which has a regulatory preference among biomanufacturers situated in the EU who are working under the guidance of the EMA, which encourages the use of animal-derived materials from the region to decrease the danger of TSE transmission. Biowest sells directly and via distribution partners in over 60 countries, with a customer base that includes pharmaceutical corporations, academic research organizations and contract biomanufacturers in Europe, North America and Asia-Pacific.

5. GE HealthCare (Cytiva) | NASDAQ: GEHC | Chicago, Illinois, USA

Company Overview. GE HealthCare's Cytiva division participates in the fetal bovine serum market through its HyClone-branded sera product line, which offers a comprehensive portfolio of standard, heat-inactivated, characterized, and specialty FBS lots for biopharmaceutical manufacturing, vaccine production, and research applications. Cytiva's cell culture portfolio integrates FBS and sera with upstream bioprocessing equipment, including bioreactors, filtration systems, and chromatography media, providing biomanufacturers with an end-to-end bioprocessing solution from cell culture media through to downstream purification. The company serves over 100 countries through Cytiva's global commercial infrastructure, with particularly strong penetration in biopharmaceutical manufacturing and contract development and manufacturing organizations (CDMOs).

6. Avantor (VWR / J.T.Baker) | NYSE: AVTR | Radnor, Pennsylvania, USA

Company Overview. Avantor is a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies end markets. It offers fetal bovine serum and laboratory chemicals, bioprocessing and research consumables to pharmaceutical manufacturers, academic institutions and biotechnology companies under its VWR and J.T.Baker brands. The company has one of the largest global networks for distribution of laboratory supplies, providing just-in-time cold-chain delivery capabilities to over 300,000 customer locations in over 30 countries – a feature that cell culture laboratories that need consistent FBS lot availability value. As a part of the bioprocessing materials business, Avantor provides large-volume FBS procurement services to vaccine makers, CDMO organizations and biopharmaceutical firms on a contracted supply basis. .

7. Serumwerk Bernburg AG | Private | Bernburg, Germany

Company Overview. Serumwerk Bernburg AG is a specialist German manufacturer of fetal bovine serum and other biological products for pharmaceutical and research applications, operating one of Europe's longest-established animal serum production facilities with over 60 years of manufacturing heritage in Bernburg, Saxony-Anhalt. The company produces FBS and fetal calf serum (FCS) from EU-certified bovine sources, with manufacturing processes compliant with European Pharmacopoeia guidelines and EMA guidance on the use of bovine serum in pharmaceutical manufacturing. Serumwerk's product portfolio spans standard FBS, heat-inactivated FBS, dialyzed sera, and specialty-grade lots, with quality testing protocols that include mycoplasma, virus, sterility, and endotoxin screening aligned with regulatory requirements for biopharmaceutical-grade cell culture applications.

8. Bovogen Biologicals (now Corning) | Acquired | Melbourne, Victoria, Australia

Company Overview. Bovogen Biologicals, acquired by Corning Incorporated in Q2 2025, was one of the world’s top independent providers of Australian-origin fetal bovine serum and other animal sera for biomedical research and pharmaceutical applications. The company established its market presence by supplying FBS from Australian and New Zealand bovine sources, which command a quality premium globally due to the stringent biosecurity regimes governing the bovine herds in these countries, including BSE-free status and comprehensive surveillance programs, resulting in southern hemisphere-origin serum being highly preferred by pharmaceutical and ATMP manufacturers. Bovogen manufactures a range of normal, heat-inactivated, dialyzed and specialized FBS products tested to pharmaceutical-grade quality standards for its customers in the Asia-Pacific, United States and Europe.

9. LGC Limited (ATCC Products) | Private | Teddington, UK

Company Overview. LGC Limited distributes fetal bovine serum through its global laboratory standards and reference materials business, including ATCC-branded FBS and cell culture products distributed to research institutions, diagnostic laboratories, and biomanufacturers across more than 100 countries. LGC's position in the FBS market derives primarily from its distribution of ATCC (American Type Culture Collection) reference cell culture products, which include FBS lots characterized and validated against ATCC reference cell lines to ensure compatibility with authenticated cell culture applications.

10. Gemini Bio (Cell Culture Company) | Private | Sacramento, California, USA

Company Overview. Gemini Bio, a US-based specialty manufacturer of fetal bovine serum and other sera obtained from animals for use in academic research, pharmaceutical development and biotechnology, has been restructured as the Cell Culture Company. The company only produces serum of North American origin. It offers US origin FBS, irradiated FBS, charcoal stripped FBS, dialyzed FBS and custom specialty serum lots characterized for specific cell culture applications including stem cell research, viral vaccine production and monoclonal antibody development. Gemini Bio sells its products via direct sales and specialty cold-chain distribution channels to customers in the United States and over 20 international countries. The Company’s customer base includes mostly academic research institutes, government laboratories and biopharmaceutical start-ups.

M&A Activity Tracker (2022–2026)

The Fetal Bovine Serum Market has experienced targeted consolidation as life sciences platform companies pursue inorganic growth to secure geographic supply chain diversification, acquire premium-origin serum sources, and vertically integrate bovine serum processing capabilities into broader cell culture and bioprocessing portfolios. Market Research Future tracks the following verified transactions directly relevant to the fetal bovine serum market:

Key Trend: MRFR analysis identifies supply chain vertical integration and geographic origin diversification as the dominant M&A themes in the FBS market, with acquirers prioritizing Australian and New Zealand bovine serum source assets that command regulatory premium and supply resilience value for pharmaceutical-grade cell culture customers increasingly focused on animal-derived material traceability.

R&D Investment & Innovation Signals

R&D investment across the Fetal Bovine Serum Market has increased materially in 2025–2026 as manufacturers invest in serum-free and reduced-serum media alternatives, advanced virus inactivation technologies, and AI-driven lot characterization systems, addressing the dual challenge of regulatory scrutiny on animal-derived materials and increasing pharmaceutical demand for defined, reproducible cell culture components. Market Research Future tracks the following verified 2025–2026 R&D and technology programs from official company sources:

• Thermo Fisher Scientific (Gibco) invested in expanded US FBS processing infrastructure in 2024–2025, implementing advanced viral filtration and nanofiltration technologies at its production facilities to achieve higher virus clearance validation standards for pharmaceutical-grade FBS lots used in cell and gene therapy manufacturing.
• Corning Incorporated integrated Bovogen Biologicals' Australian-origin FBS characterization protocols into its Life Sciences quality management system in 2025, developing a unified lot release testing framework that covers multi-origin FBS — including US, Australian, and New Zealand sources — within a single globally harmonized quality assurance standard.
• Merck KGaA (Sigma-Aldrich) advanced its serum characterization technology platform in 2025, introducing multi-parameter growth performance testing that quantifies FBS lot efficacy across five standardized cell line models — including CHO, HEK293, Vero, and mesenchymal stem cells — providing pharmaceutical customers with predictive lot-selection data that reduces cell culture optimization time.
• Biowest invested in animal welfare-compliant bovine collection protocols across its EU-certified supplier network in 2025, developing a proprietary audit and traceability system that generates fully digitized collection records from abattoir to finished FBS lot, enabling customers to provide complete animal welfare documentation chains to institutional ethics committees.
• GE HealthCare (Cytiva) developed next-generation HyClone FBS products with enhanced growth factor characterization in 2025, introducing standardized minimum growth factor specifications for EGF, PDGF, FGF, and IGF-1 content across premium-grade lots — addressing the primary technical limitation of conventional FBS which is batch-to-batch growth factor variability.
• Avantor invested in cold-chain digital monitoring infrastructure for FBS distribution in 2025, deploying IoT-enabled temperature sensors and real-time excursion alert systems across its global FBS logistics network to reduce product loss from cold-chain failures and provide customers with verifiable temperature-compliance certificates on all serum shipments.